NovoCure

Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. TTFields are low-intensity, intermediate-frequency alternating electric fields that disrupt mitosis and cytokinesis. TTFields exert sufficient physical force on charged cellular components to stop normal cell-division processes, specifically the formation of the mitotic spindle from tubulin dimer proteins. TTFields also exert a physical force on other components of the cell during division, causing cell death prior to division. TTFields therapy is delivered using noninvasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The complete delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries, and more. The portable therapy is designed to be worn continuously throughout the day and night. Novocure received an FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small cell lung cancer.

NovoCure has raised $742M in total funding across 5 rounds. The company is currently at the Public stage. Key investors include BioPharma Credit PLC.

NovoCure was founded in 1999 by Prof. Yoram Palti (Founder ).

NovoCure operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Semiconductors & Electronics, Wearables. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Providers.

NovoCure is based in Matam Center, Haifa, Israel, North District. The company also has offices abroad.